Alexion Pharmaceuticals Completes Acquisition of Portola Pharmaceuticals

Paul, Weiss advised Alexion Pharmaceuticals, Inc. in its acquisition of Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders. Under the terms of the transaction, Alexion acquired all of Portola’s outstanding shares of common stock at $18.00 per share in cash, without interest.

The Paul, Weiss team included, among others, corporate partners Scott Barshay, John Kennedy and Raphael Russo, and counsel Patricia Vaz de Almeida; intellectual property partner Jonathan Ashtor; employee benefits partner Jean McLoughlin and counsel Jarrett Hoffman; litigation partner Jaren Janghorbani and counsel Rachel Fiorill; tax partner Robert Holo; real estate partner Peter Fisch; and antitrust counsel Yuni Sobel and Marta Kelly.